1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Anupam Rasayan India Ltd.

Anupam Rasayan India Ltd.

1,107.60
INR
+3.65
(+0.33%)
19.17EPS
86.93P/E
144.18BMarket Cap
Nov 11Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
34.38
50.48
53.35
98.89
105.1
150.71
133.38
127.65
205.96
202.89
Basic EPS, GAAP
4.13
4.93
5.32
8.56
15.22
17.44
11.89
8.5
15.09
14.57
Free Cash Flow per Basic Share
-27.61
-20.95
-8.55
-17.59
-31.82
6.88
-60.74
-40.06
-19.59
- -
Dividend per Share
- -
- -
- -
- -
1
2.37
2.43
1.22
1.35
- -
Book Value per Share
43.33
48.29
56.58
157.46
172.26
220.78
251.49
259.28
290.02
- -
Tangible Book Value per Share
41.84
46.96
55.3
156.3
171.11
207.98
238.32
245.99
225.66
- -
Basic Weighted Avg Shares
100
100
100
82
100
104
108
110
113
113
Sales/Revenue/Turnover
3,435
5,044
5,331
8,124
10,508
15,629
14,426
14,023
23,214
22,890
Operating Margin (%)
17.83
16.16
22.19
18.83
23.31
23.05
20.9
21.35
17.25
16.93
Depreciation Expense
176
225
287
517
601
711
797
1,023
1,399
1,639
Net Income, GAAP
413
492
532
703
1,522
1,808
1,286
933
1,701
1,644
Effective Tax Rate (%)
18.93
23.6
25.76
29.71
31.41
29.52
30.75
19.15
12.66
12.99
Profit Margin (%)
12.03
9.76
9.98
8.65
14.48
11.57
8.91
6.66
7.33
7.18
Working Capital
792
841
578
6,699
8,516
13,004
9,104
7,647
11,121
- -
LT Debt
2,678
4,623
5,577
2,796
5,140
3,819
2,370
2,230
5,594
- -
Total Equity
4,576
5,071
5,935
15,734
17,268
25,081
29,307
30,817
46,300
- -
Return on Invested Capital (%)
- -
6
6.63
6.2
7.32
8.69
5.79
5.73
6.34
- -
Return on Capital (%)
- -
5.86
6.11
6.42
7.4
6.09
3.95
2.58
4.4
- -
Return on Common Equity (%)
- -
10.76
10.15
6.57
9.22
8.82
5.01
3.33
5.53
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
13,382
- -
LT Borrowings
- -
5,108
- -
LT Finance Leases
- -
486
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
114
114
114
Market Capitalization
150,271
139,310
144,177

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
37,275
- -
Cash, Cash Equivalents & STI
- -
3,995
- -
Accounts Receivable, Net
- -
9,594
- -
Inventories
- -
17,748
- -
Total Current Liabilities
- -
26,154
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
13,382
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
25.45%
50.24%
Free Cash Flow
- -
-221.3%
-49.82%
Net Income, GAAP
- -
32.25%
82.24%
Sales/Revenue/Turnover
- -
26.62%
65.54%
Total Cash Common Dividend
- -
- -
13.27%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2,542
2,940
3,901
5,002
14,023
2026
4,858
- -
5,124
6,358
23,214
2027
6,550
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
0.36
1.51
2.57
4.06
8.5
2026
3.1
- -
4.31
3.75
15.09
2027
3.39
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
1.22
2026
- -
- -
- -
- -
1.35
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Gopal Agrawal
Full Time Employees
2,931
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Icon Rio, Behind Icon Business Centre Surat GU India 395007
IPO Date
Mar 24, 2021
Website
anupamrasayan.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Anupam Rasayan India Limited specializes in the custom synthesis and manufacturing of advanced specialty chemicals. The company develops and produces a diverse range of materials for life science sectors, encompassing agrochemical intermediates and active ingredients, antibacterial and UV protection compounds for personal care, and key starting materials for active pharmaceutical ingredients. Additionally, it offers various other specialty chemicals, including high-performance pigments, dyes, and polymer additives. Anupam Rasayan is actively expanding its footprint into emerging areas such as electronic chemicals and high-performance materials for defense, aerospace, and semiconductor industries. Leveraging expertise in complex chemistries and advanced manufacturing, including continuous and flow chemistry technology, the firm serves a broad base of Indian and international clients across Europe, Japan, Singapore, China, and North America. Founded in 1984 and headquartered in Surat, India, the company maintains robust R&D capabilities and strategic backward integration. Recent achievements include consistent financial performance, a significant order book extending over several years, and new molecule launches, reflecting its commitment to innovation and market growth. The company is also focused on sustainability, with initiatives aimed at achieving energy neutrality by 2027.